Nicolet Advisory Services’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$327K Sell
711
-124
-15% -$53.4K 0.02% 314
2025
Q3
$343K Sell
835
-250
-23% -$104K 0.03% 297
2025
Q2
$501K Buy
1,085
+148
+16% +$68.2K 0.04% 216
2025
Q1
$446K Buy
937
+234
+33% +$109K 0.04% 208
2024
Q4
$288K Buy
703
+62
+10% +$28.7K 0.03% 302
2024
Q3
$291K Buy
641
+28
+5% +$13.4K 0.03% 294
2024
Q2
$301K Buy
613
+67
+12% +$29.1K 0.03% 276
2024
Q1
$221K Sell
546
-51
-9% -$21.6K 0.02% 321
2023
Q4
$249K Buy
597
+25
+4% +$9.23K 0.03% 280
2023
Q3
$202K Buy
+572
New +$200K 0.02% 297

Other funds holding VRTX

Nicolet Advisory Services's VRTX Position: Q4 2025 in Review

Nicolet Advisory Services reduced its Vertex Pharmaceuticals (VRTX) stake by 15% in Q4 2025, selling an estimated $53.4K and leaving 711 shares worth $327K. The position accounts for 0.02% of the portfolio, ranked #314.

Nicolet Advisory Services first reported a position in VRTX in Q3 2023 and has held it in 10 quarters since. The position peaked at $501K in Q2 2025. 1,668 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

  • Nicolet Advisory Services held 711 shares of Vertex Pharmaceuticals worth $327K as of Q4 2025.
  • Nicolet Advisory Services sold 124 Vertex Pharmaceuticals shares in Q4 2025, an estimated $53.4K.
  • Vertex Pharmaceuticals made up 0.02% of Nicolet Advisory Services's portfolio in Q4 2025, its #314 holding.
  • Nicolet Advisory Services first reported a position in Vertex Pharmaceuticals in Q3 2023 and has held it in 10 quarters since.
  • Nicolet Advisory Services's Vertex Pharmaceuticals position peaked at $501K in Q2 2025.
  • 1,668 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Nicolet Advisory Services's 13F filing for Q4 2025, filed 13 Feb 2026.